Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.

The investment narrative surrounding Hims & Hers Health, Inc. presents a complex puzzle. On one hand, institutional money is flowing in and the company i ...

Ascendis Pharma's Yorvipath and Skytrofa drove Q3 revenues to €213.6 million, nearly quadrupling year-over-year. Read why ...

Stocks to Watch today, December 15, 2025: Indian equities are set for a weaker start on Monday, tracking negative global cues ...

Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that ...

Undeterred by domestic regulatory concerns, Hims & Hers is actively executing its global strategy. On December 10, the company launched its comprehensive weight-loss program in the United Kingdom, ...

Ozempic (injectable semaglutide) is a once-weekly treatment indicated as an add-on to diet and exercise for adults with uncontrolled Type 2 diabetes mellitus (T2DM).

From the rupee's continued slide, the Cabinet's approval of two reform bills, to Ozempic's launch in India, here are the key news events that shaped the week gone by.

Novo Nordisk launched Ozempic in India on Friday—and the weight-loss drug will sell at a massive discount there, compared ...

Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud ...

There’s trouble brewing beneath the GLP-1 buzz. As Americans embrace blockbuster weight-loss drugs like Ozempic and Wegovy in ...

A perfect storm of clinical setbacks, intensifying competition, and internal upheaval has triggered a historic sell-off in ...